Survival Duration and Influencing Factors in Cervical Cancer Patients in Tigray, Ethiopia: A Retrospective Analysis - Summary - MDSpire

Survival Duration and Influencing Factors in Cervical Cancer Patients in Tigray, Ethiopia: A Retrospective Analysis

  • By

  • Gerezgiher Buruh Abera

  • Mussie Alemayehu

  • Demisew Amenu Sori

  • Rahma Ali

  • Nega Jibat

  • Wondimagegn Adissu

  • Haftamu Hailekiros

  • Endashaw Nadew

  • Ashenafi Alemu

  • Alemseged Abdissa

  • Nigisti Mulholland

  • Gelila K Goba

  • Eva J Kantelhardt

  • Kim Mulholland

  • Prisha Balgovind

  • Gerald L. Murray

  • Suzanne M. Garland

  • March 2, 2026

  • 0 min

Share

Objective:

To analyze survival duration and identify factors influencing time to death among cervical cancer patients in Tigray, Ethiopia.

Key Findings:
  • Cervical cancer is the second leading cause of cancer mortality among Ethiopian women.
  • Survival rates in Ethiopia are below 20% due to late diagnosis and inadequate treatment access.
  • The armed conflict in Tigray severely disrupted health services, impacting cancer care.
Interpretation:

The study highlights the urgent need for localized data on cervical cancer survival outcomes in Tigray, especially given the compounded crises affecting healthcare access.

Limitations:
  • Geographic remoteness and financial constraints limit healthcare access.
  • Lack of widespread awareness and screening services contributes to late-stage diagnoses.
  • The study may not capture all affected areas due to security concerns.
Conclusion:

Understanding survival rates and influencing factors is crucial for developing targeted interventions to improve cervical cancer outcomes in Tigray.

Original Source(s)

Survival Duration and Influencing Factors in Cervical Cancer Patients in Tigray, Ethiopia: A Retrospective Analysis

  • by Gerezgiher Buruh Abera, Mussie Alemayehu, Demisew Amenu Sori, Rahma Ali, Nega Jibat, Wondimagegn Adissu, Haftamu Hailekiros, Endashaw Nadew, Ashenafi Alemu, Alemseged Abdissa, Nigisti Mulholland, Gelila K Goba, Eva J Kantelhardt, Kim Mulholland, Prisha Balgovind, Gerald L. Murray, Suzanne M. Garland

  • March 2, 2026

Related Content

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Vaginal DNA Assay Shows Promise

A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.

The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases